ClinicalTrials.gg
WithdrawnNCT06701461Updated Nov 13, 2026

Measurement of Osteoarthritic Patient Pain Through Electrodermal Activity Signals

An interventional study of Electrodermal Activity signal in Osteo Arthritis Knee, sponsored by Dartmouth-Hitchcock Medical Center. Withdrawn at 1 site in United States. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Dartmouth-Hitchcock Medical Center · Not applicable, Interventional, and Diagnostic

How we know

Why this study was withdrawn
The study was not pursued
Updated Nov 13, 2026Now WithdrawnEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,886 studies in Pain with a site in United States — 315 open to participants now, 393 under way, 24 of them phase 3. Pain · United States.

Enrollment
2,443rd of 2,564
0 · median 66
Started
2026
with 114 others
No phase
1,244 of 2,886
183 open now
Registered
2,653rd of 2,886
by date

Among the 2,886 studies in Pain with a site in United States, this one is the 2,443rd largest by enrollment of the 2,564 interventional ones that give a count, is one of 115 that started in 2026, is one of 1,244 with no phase, and was the 2,653rd registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

315 of the 2,886 studies in Pain with a site in United States are open now. Recruiting first, the newest first:

310 more — sign in →

All 315 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,886 studies in Pain with a site in United States, or all of them as a file.
02

Study summary

This pilot study aims to investigate the viability of using a smartwatch-based electrodermal activity (EDA) sensor to capture enough EDA signal to quantitatively assess pain in osteoarthritis subjects and test the feasibility of its methods and procedures for later use in subsequent larger-scale studies.

Read the detailed description

Chronic pain, a disease in its own right, afflicts one in three adults in the US and poses an enormous economic burden ($560-$635 billion annually), more than heart disease, cancer, and diabetes. To treat pain, doctors often prescribe opioids to suffering patients. Paradoxically, prescription opioid abuse has become a national epidemic, costing $500 billion annually in medical, economic, social, and criminal ramifications. However, the development of effective treatment for chronic pain is hampered by the lack of a reliable biomarker that can quantify the level of pain and detect any attenuation after treatment. This is reflected in the failed statistical significance in many clinical trials of drugs for managing chronic pain (e.g., ONO-2952 and Ibodutant) or a large enrollment number being required to reveal significant but small effects (e.g., 1,798 enrollments for the trial on Renzapride).

Dysfunction of the autonomic nervous system (ANS) has been linked with many chronic pain conditions. The ANS is the primary pathway in brain-gut communication and manifests the body's emotional and psychological states. This makes it particularly relevant to pain, which has a strong emotional component. The ANS includes the sympathetic (SNS) and parasympathetic nervous systems (PNS), and chronic pain conditions reportedly correlate with an unchecked predominance of SNS activity and desensitized PNS. Thus, the PNS and SNS are promising targets for developing sensitive and robust biomarkers for chronic pain.

The investigators will leverage the EmbracePlus smartwatch for the non-invasive quantification of both SNS and PNS activities with time- and frequency-domain analysis of EDA. In this proposed pilot study, the investigators aim to establish whether this biomarker for quantifying pain levels shows promise for osteoarthritis patients when detected through a smartwatch. This is intended to be preliminary work to support a grant application for a more extensive study. In this work, the investigators will collect EDA measurements across up to 15 subjects (2/3 with symptomatic osteoarthritis (Kellgren-Lawrence grade >= 3) and 1/3 control). Each participant's baseline response will first be measured using a thermal grill (a research device commonly used to induce a painful stimulus without injury). Participants will also report their results using a VAS. Then, Participants will be put through three OARSI standardized functional tests: the 30-second chair test, the 40m fast-paced walk, and the stair climb test. During these tests, subjects will receive a handheld clicker to mark moments of their sharpest pain. The results of each test will then be analyzed through a set of time- and frequency-domain analyses of the recorded bio-signals to extract key parameters and measure how well EDA signal detection captured both sharp and dull pain in subjects.

If effective, this method can be particularly useful. Existing commercial wearable sensors can collect patient data for a week at a time. This would allow for the collection of in-vivo and continuous patient pain data, which could greatly enhance the understanding of patient pain both pre- and post-treatment.

03

Conditions studied

  • Osteo Arthritis Knee

Keywords

  • Pain
  • Electrodermal Activity Signals
  • Osteoarthritis
  • Knee
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Study subjects

Inclusion Criteria:

  • Kellgren-Lawrence Grade >= 3

Exclusion Criteria:

  • Inflammatory arthropathy (e.g., rheumatoid arthritis), >=35

Control subjects:

Exclusion Criteria:

  • Complaints of lower extremity joint pain
  • Known diagnosis of knee osteoarthpathy
  • Prior history of knee surgery, knee injections, or injury to knee joints (e.g., meniscus tears, ligamentous injuries), BMI >=35

Both groups, exclusion:

  • Subjects with chronic heart problems, including, but not limited to, chronic hypertension, heart palpitations, a weak or irregular heartbeat, or a previous heart attack,
  • Subjects taking the following drugs within 12 hours of the experiment or during the experiment: caffeine, alcohol, psychoactive drugs, nicotine or marijuana, other recreational drugs, and medicine of any kind that is not normally taken daily. Such medications include;

    • NSAIDs
    • Acetaminophen
    • Steroidal anti-inflammatory agents
    • Bronchodilators
    • Appetite suppressants
    • Lipase inhibitors
  • Women who are currently pregnant
  • Subjects with Raynaud's syndrome
  • Subjects with any of the following conditions: active skin lesions where EDA sensors are, vertigo or dizziness, and anyone with postural orthostatic tachycardia syndrome (POTS), peripheral neuropathy, seizure disorders, methicillin-resistant staphylococcus aureus (MRSA), impaired circulation, medical implants, open skin lesions, chronic eczema on hands where EDA and electrical stimulator's electrodes are attached, diabetes, and epilepsy.
  • Participants who have a skin sensitivity to metals, have a pacemaker or defibrillator, or have recent head trauma within the past two weeks (even without loss of consciousness)
  • Participants who cannot feel physical pain or have a history of self-harm
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Electrodermal Activity Measurement Subjects

    Participants will have their baseline electrodermal activity (EDA) response to pain measured as well as their EDA response measured while participating in a set of standardized functional tests.

    Device: Electrodermal Activity signal

Interventions

  • DeviceElectrodermal Activity signal

    Determining if the electrodermal activity signals, as measured by the Embrace Plus smartwatch) can be used to measure osteoarthritic patient pain levels.

06

What researchers measure

Primary outcomes

  1. :Difference in pain measurements as reported by the participant via a visual analogue scale versus smartwatch reported electrodermal activity sensors

    As a pilot study, the goal is not hypothesis testing but rather examining the feasibility of this approach to measuring patient pain in osteoarthritic patients. Thus, the statistical analysis will be primarily descriptive. The baseline experiment is being done to see whether the smartwatch measurements are at all comparable to prior similar experiments using the thermal grill (Posada-Quintero 2016; Posada-Quintero 2021). For this reason, though not typical for a pilot study, participant responses to the baseline test will use similar analysis to prior electrodermal activity (EDA) based thermal grill studies to see if the smartwatch poses a viable EDA signal collection source. This primarily consists of repeated measures analysis of variance (ANOVA) comparing patient-reported visual analog scale (VAS) scores to EDA output.

    Time frame: 40 minutes of test time, occurring all in one day.

  2. Patient-reported pain during standardized Osteoarthritis Research Society International (OARSI) 30-second chair test

    Patients will be asked to participate in the standardized OARSI 30-second chair test. During the OARSI functional tests, the timestamps of patient reports of pain will be recorded by the experimenter.

    Time frame: 5 minutes

  3. Electrodermal activity (EDA) signals during standardized Osteoarthritis Research Society International (OARSI) 30-second chair test

    A smartwatch will capture the patient's EDA signals during the 30-second chair test

    Time frame: 0 minutes. Concurrent with measurement of patient-reported pain.

  4. Patient-reported pain during standardized Osteoarthritis Research Society International (OARSI) 40m fast-paced walk test

    Patients will be asked to participate in the standardized OARSI 40m fast-paced walk test. During the OARSI functional tests, the timestamps of patient reports of pain will be recorded by the experimenter.

    Time frame: 10 minutes

  5. Electrodermal activity (EDA) signals during standardized Osteoarthritis Research Society International (OARSI) 40m fast-paced walk test

    A smartwatch will capture the patient's EDA signals during the 40m fast-paced walk test

    Time frame: 0 minutes. Concurrent with measurement of patient-reported pain.

  6. Patient-reported pain during standardized Osteoarthritis Research Society International (OARSI) stair climb test

    Patients will be asked to participate in the standardized OARSI stair climb test. During the OARSI functional tests, the timestamps of patient reports of pain will be recorded by the experimenter.

    Time frame: 10 minutes

  7. Electrodermal activity (EDA) signals during standardized Osteoarthritis Research Society International (OARSI) stair climb test

    A smartwatch will capture the patient's EDA signals during the stair climb test

    Time frame: 0 minutes. Concurrent with measurement of patient-reported pain.

  8. Accuracy of predicting patient pain from electrodermal activity signal (EDA) during standardized Osteoarthritis Research Society International (OARSI) function tests

    We will treat the processed EDA signal as a binary classifier (i.e., prediction of pain or no pain at any given moment). The accuracy of these predictions will be calculated against the actual patient-reported pain.

    Time frame: 0 minutes. Done after all data has been collected.

  9. Percentage of correctly identified pain events (Sensitivity) as measured by the smartwatch (True positive events)

    In these tests, we will treat the processed EDA signal as a binary classifier (i.e., prediction of pain or no pain at any given moment). The sensitivity of these predictions will be calculated against the actual patient-reported pain.

    Time frame: 0 minutes. Done after all data has been collected.

  10. Percentage of correctly identified non-pain events (Specificity) as measured by the smartwatch (True negative non-events)

    In these tests, we will treat the processed EDA signal as a binary classifier (i.e., prediction of pain or no pain at any given moment). The specificity of these predictions will be calculated against the actual patient-reported pain.

    Time frame: 0 minutes. Done after all data has been collected.

07

Study locations

1 site
08

References and documents

Publications

  • Posada-Quintero HF, Florian JP, Orjuela-Canon AD, Chon KH. Highly sensitive index of sympathetic activity based on time-frequency spectral analysis of electrodermal activity. Am J Physiol Regul Integr Comp Physiol. 2016 Sep 1;311(3):R582-91. doi: 10.1152/ajpregu.00180.2016. Epub 2016 Jul 20. PubMed 27440716 ↗
  • Posada-Quintero HF, Kong Y, Chon KH. Objective pain stimulation intensity and pain sensation assessment using machine learning classification and regression based on electrodermal activity. Am J Physiol Regul Integr Comp Physiol. 2021 Aug 1;321(2):R186-R196. doi: 10.1152/ajpregu.00094.2021. Epub 2021 Jun 16. PubMed 34133246 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Sep 2026, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2024
First posted
Nov 22, 2024
StartEst.
Aug 2026
Primary completionEst.
Sep 2026
CompletionEst.
Oct 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn The study was not pursued
changed Nov 13, 2026
Enrollment
15 (estimated)→0 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Not yet recruiting→Withdrawn
    Why stopped The study was not pursued
    Enrollment 15 (estimated)→0 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06701461
Responsible party
Peter L. Schilling (Assistant Professor of Orthopaedics, Geisel School of Medicine, Dartmouth, Dartmouth-Hitchcock Medical Center) — Principal investigator
First posted
Nov 22, 2024
Start date
Aug 2026 (estimated)
Primary completion
Sep 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Nov 13, 2026

Study contacts

Peter L Schilling, MD, MS
principal investigator · Dartmouth-Hitchcock Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion